Alliance Pharma Share Discussion Threads

[tomzimerman] 07/6/2024 15:31

They only seem to reply to specific investors. Unless someone's telling pork pies for 1205th time lol

[justiceforthemany] 07/6/2024 15:11

You spoke to Cora? Why are they not responding to emails?

[baldrick1] 07/6/2024 13:42

Nope! ;))]

[baldrick1] 07/6/2024 13:34

Or maybe ;))))

[baldrick1] 07/6/2024 12:42

Obviously not :)))

[baldrick1] 07/6/2024 12:40

Shouldn't it be torching time? ;)))

[baldrick1] 07/6/2024 12:38

I'm in BH;)))

[blackhorse23] 07/6/2024 12:28

I got email reply & spoke to investor relations, accounting delays due to current stock accounting & valuations , but last year number is correct as mentioned in 29th January. Account is ready , once signed off by CEO it will be published & they are aware has to publish before end of the month. So ALL GOOD FOR ME

[baldrick1] 07/6/2024 11:58

I'm out with the ne donkeys ;))

[baldrick1] 07/6/2024 11:07

And in with the same new donkeys ;))

[baldrick1] 07/6/2024 11:06

I'm out with the new donkeys;))

[tomzimerman] 07/6/2024 10:40

Last top up for the donkey below lol

[blackhorse23] 07/6/2024 10:22

WIN WIN BUY

[baldrick1] 07/6/2024 10:12

I'm in ;)))

[baldrick1] 07/6/2024 09:32

FOMO mode:)

[seagreen] 07/6/2024 09:17

fatfish I was referencing other people's thoughts if you look higher up not mine I concur Deloittes will not be responsible etc

re
"mmmmmmm don't quite know what you're referring to, can't imagine deloittes will be responsible for anything, unless they fraudulently fudge the figures"

[baldrick1] 07/6/2024 08:33

Traders are seeing very good value at this level again, and the buying starts :)

[blackhorse23] 07/6/2024 08:29

Results will be as below plus add 8m from court winning: Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance.OutlookDemand for the Group's brands remains strong. Alliance's clear focus on the core Consumer Healthcare business, in addition to our well-established, scalable platform across EMEA, APAC and the US, is expected to deliver continued strong organic growth over the medium term. In 2024, the Board anticipates our Consumer Healthcare revenues to continue to grow above that of the broader Consumer Healthcare market, with stable Prescription Medicine revenues.In order to achieve our medium-term objectives, in 2024, the Board anticipates increased investment in sales and marketing, both directly and through the Group's distributors. The Company will also continue to deliver innovation in 2024 to further expand the reach of its brands. As a result, the Board anticipates that profits in 2024 will be in-line with 2023.

[baldrick1] 07/6/2024 08:25

Interest rates could start to come down next month, imho

[baldrick1] 07/6/2024 08:23

Results will be next week after the fat mouth has spoken ;))